Track topics on Twitter Track topics that are important to you
NewsTeva Pharmaceutical Industries Ltd., Celltrion, Inc., and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb bios...
David SalazarTeva and Celltrion on Thursday announced a new exclusive partnership centered on commercializing two of Celltrion’s biosimilar candidates in the United States and Canada. read...
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion Inc. and Celltrion Healthcare announced that they have entered into an exclusive partnership to commercialize two of C...
Israeli generics giant Teva Pharmaceutical Industries (Teva) and South Korean biotechnology company Celltrion announced on 7 October 2016 that they had entered into an exclusive partnership for two of...
* Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima
More biosimilars from a South Korean drugmaker could join Celltrion's Remicade biosimilar Inflectra, or Remsima, in the US ma -More-
* Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars
* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug